Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients

References

• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–27.
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29 (6 Suppl 16):15–8.
   PubMed Web of Science ®Google Scholar
• Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000;50: 63–70.
   PubMed Web of Science ®Google Scholar
• Cowey CL, Sonpavde G, Hutson TE. New advancements and developments in treatment of renal cell carcinoma: Focus on pazopanib. Onco Targets Ther 2010;3:147–55.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061–8.
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379: 1879–86.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126–32.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562–9.
   PubMed Web of Science ®Google Scholar
• Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010;15:810–8.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Votrient [package insert]. Research Triangle Park, NC, 2012.
   Google Scholar
• Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 2010;12:855–61.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119:32–7.
   PubMed Web of Science ®Google Scholar
• Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010;28:3131–7.
   PubMed Web of Science ®Google Scholar
• Lim WT, Thng C, Toh CK, Chowbay B, Goh BC, Leong S, et al. A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma. ASCO Meeting Abstracts. 2010;28 (15 Suppl):5556.
   Google Scholar
• Phan AT, Yao JC, Fogelman DR, Hess KR, Ng CS, Bullock SA, et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). ASCO Meeting Abstracts. 2010 June 14. 2010;28 (15 Suppl):4001.
   Google Scholar
• Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010;11:962–72.
   PubMed Web of Science ®Google Scholar
• Van Der Graaf TA. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). Chicago: ASCO; 2011.
   Google Scholar
• Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475–80.
   PubMed Web of Science ®Google Scholar
• Committee FODA. Votrient (Pazopanib) Tablets: For treatment of patients with advanced renal cell carcinoma. Addendum to GSK briefing document for October 5, 2009. 2009 [cited 2011 Feb 21]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM184009.pdf
   Google Scholar
• Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008;300:2277–85.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 2007;49:186–93.
   PubMed Web of Science ®Google Scholar
• Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009;58:1555–64.
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995;333:1118–27.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: Insights from genetic studies. Pharmacogenomics 2009;10:1467–87.
   PubMed Web of Science ®Google Scholar
• Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 2011;54:1237–43.
   PubMed Web of Science ®Google Scholar
• Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer 2010;102:1371–7.
   PubMed Web of Science ®Google Scholar
• LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, et al. Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1. Science 2003;299: 890–3.
   PubMed Web of Science ®Google Scholar
• Dufour J-F, Clavien P-A. Signaling pathways in liver diseases, 2nd ed. New York: Springer; 2009.
   Google Scholar
• Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410–26.
   PubMed Web of Science ®Google Scholar
• Forooghian F, Das B. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha. Am J Ophthalmol 2007;144:761–8.
   PubMed Web of Science ®Google Scholar
• Taran A, Ignatov A, Smith B, Costa SD, Bischoff J. Acute hepatic failure following monotherapy with sunitinib for ovarian cancer. Cancer Chemother Pharmacol 2009;63:971–2.
   PubMed Web of Science ®Google Scholar
• Schramm C, Schuch G, Lohse AW. Sorafenib-induced liver failure. Am J Gastroenterol 2008;103:2162–3.
   PubMed Web of Science ®Google Scholar
• Motzer Rea. COMParing the efficacy, sAfety and toleRability of paZopanib vs. sunitinib (COMPAZ). The ESMO 2012 Congress of the European Society for Medical Oncology; 2012. Vienna, Austria: ESMO; 2012.
   Google Scholar
• GlaxoSmithKline. Votrient [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
   Google Scholar
• Klempner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D, Atkins MB. Severe pazopanib-induced hepatotoxicity: Clinical and histologic course in two patients. J Clin Oncol 2012;30:e264–8.
   PubMed Web of Science ®Google Scholar
• Pandite L, Goodman V, Botbyl J, Suttle AB, Gauvin J, Dar M. Trough PK concentration, age of patient, and baseline ALT are important factors in predicting ALT elevations in pazopanib treated mRCC patients. Meeting Abstracts. Lugano: European Society for Medical Oncology (ESMO); 2010.
   Google Scholar
• Pfizer. Sutent [package insert]. New York, NY: Pfizer: 2012.
   Google Scholar
• Pfizer. Inlyta (Axitinib) package insert. New York, NY: Pfizer: 2012.
   Google Scholar